Millipore joins Rohm & Haas to create chromatography solutions

Millipore Corp has announced a joint development agreement with Rohm & Haas Company to create high-performance chromatography products for use in the production of biologic drugs.

The partnership will combine Millipore's biopharmaceutical manufacturing expertise with Rohm & Haas' knowledge of ion exchange resins, polymer chemistry and manufacturing.

Under the terms of the agreement, the companies will develop improved ion exchange chromatography products for manufacturing biologic drugs. Ion exchange is used to separate molecules based on their molecular charge and is a critical step in purifying biologic drugs.

"By combining our capabilities with Rohm & Haas' expertise, we will significantly broaden the chromatography offerings we can provide to our biotech and pharmaceutical customers," said Jean-Paul Mangeolle, president of Millipore's Bioprocess Division.

"These new ion exchange offerings will build on our strong position in protein affinity chromatography and take us a step closer to providing complete, integrated solutions for our biopharmaceutical customers."

"Millipore's market insights and deep understanding of biopharmaceuticals customers' needs will accelerate the development of new advanced separation media," said Kim Ann Mink, vice-president and global general manager, Rohm & Haas Ion Exchange Resins.

"We are confident this collaboration will yield developments that will benefit customers and our respective companies."